LM302
Search documents
美银证券：中国生物制药两款药物进度积极 重申“买入”评级
Zhi Tong Cai Jing· 2026-02-12 08:35
美银证券发布研报称，中国生物制药(01177)两款药物TQB2102及LM302近期已完成第三期临床研究的 受试者入组。当中LM302是全球首个完成第三期注册性临床研究受试者入组的CLDN18.2抗体药物复合 体，有望为患者提供新的治疗选择。该行现予目标价8.6港元，重申"买入"评级。 ...
美银证券：中国生物制药(01177)两款药物进度积极 重申“买入”评级
智通财经网· 2026-02-12 08:32
智通财经APP获悉，美银证券发布研报称，中国生物制药(01177)两款药物TQB2102及LM302近期已完成 第三期临床研究的受试者入组。当中LM302是全球首个完成第三期注册性临床研究受试者入组的 CLDN18.2抗体药物复合体，有望为患者提供新的治疗选择。该行现予目标价8.6港元，重申"买入"评 级。 ...
大行评级丨美银：中国生物制药两款药物进展积极，重申“买入”评级
Ge Long Hui· 2026-02-12 08:28
Core Viewpoint - Bank of America Securities reports that two drugs from a Chinese biopharmaceutical company, TQB2102 and LM302, have recently completed patient enrollment for Phase III clinical trials, with LM302 being the first CLDN18.2 antibody-drug conjugate to complete this phase globally, potentially offering new treatment options for patients [1] Group 1 - The two drugs, TQB2102 and LM302, have completed patient enrollment for Phase III clinical trials [1] - LM302 is noted as the world's first CLDN18.2 antibody-drug conjugate to complete Phase III registration clinical trial enrollment [1] - The target price for the company is set at HKD 8.6, with a reiterated "Buy" rating [1]